News

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...
This combination "provided weight loss in the highest range of efficacy observed with existing weight loss interventions," ...
Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...
Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity ...
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...
Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro’s ...